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Abstract- An increasing number of procedures using propofol 
and remifentanil are performed by clinicians with no formal in 
anesthesiology. The rapid kinetics of these drugs can rapidly 
lead to adverse effects the clinician is not trained to manage. 
We therefore propose to investigate through simulations drug 
ratios and dosing regimens that allow esophageal 
instrumentation while minimizing the probability of adverse 
events. Our simulation criteria were to reach and minimize the 
time above the esophageal instrumentation C95 isobol, as well as 
minimize the time above the loss or responsiveness C99 and 
respiratory compromise C95 isobols. A cost functional would be 
developed to score each simulation. This score could be used to 
identify preferred solutions. Simulations were first sorted 
manually and then different cost functionals were developed to 
achieve similar results. A relatively simple equation selected 
80% of the runs identified manually. Further work is needed in 
developing the cost functional to increase this percentage and to 
add meaning to the score.  
 
 
 
I. INTRODUCTION 
 
Propofol in combination with opioids are commonly 
administered by clinicians with no formal training in 
anesthesiology for stimulating procedures of brief duration 
where moderate sedation is desired. Propofol interacts 
synergistically with opioids and can lead to worrisome 
adverse effects including cardiovascular depression, 
respiratory depression, and airway obstruction.  Many 
clinicians who use these drugs do not have the skills to 
properly manage these adverse events. It would therefore be 
ideal to provide these clinicians with drug ratios and dosing 
strategies for these procedures that would minimize adverse 
effects in the majority of patients. 
Recent advances in characterizing drug interactions and 
high resolution modeling to predict drug behavior have 
provided the theoretical means to optimize dosing to achieve 
desired effects quickly, maintain those effects while avoiding 
unwanted side effects, and minimize the time required for 
the effects to end once delivery is terminated. 
Simulations allow a wide range of dosing strategies to be 
investigated for viability before conducting an actual study. 
The ease of simulating, however, presents a new problem. 
Thousands of simulations can be run rapidly, but a method is 
needed to quickly identify viable solutions. 
We propose to develop a cost functional that will return 
meaningful scores for simulations of a specific procedure – 
esophageal instrumentation (EI). We hypothesize that this 
score can be used to 1) Identify the optimal dosing regimen 
of propofol and remifentanil (bolus versus infusion versus 
bolus followed by infusion, 2) Minimize the time of loss of 
responsiveness and respiratory compromise while allowing 
EI. 
 
II. BACKGROUND 
 
An increasing trend in patient care is to perform 
procedures associated with mild to moderate pain outside the 
operating room. Potent fast-acting anesthetics are commonly 
used to blunt the response to noxious stimuli associated with 
these procedures, but are often administered by clinicians 
with no formal training in anesthesiology.  
This study explored the behavior of two commonly used 
intravenous anesthetics, propofol and remifentanil, when 
used in combination to blunt the response to esophageal 
instrumentation. Both drugs have unique and desired 
properties. Propofol is an anesthetic, providing loss of 
consciousness, preventing awareness and reducing 
movement response to surgical stimuli. However, at higher 
doses it frequently causes airway obstruction and loss of 
consciousness. Remifentanil at higher doses can cause 
respiratory depression leading to apnea. 
An advantage to using these drugs in combination is their 
synergistic relationship. The effects of each drug are 
enhanced when they are administered together. Less of each 
drug is required to achieve a desired level of sedation than if 
one drug is used in isolation.  
Recent developments in clinical pharmacology research 
have led to the development of response surface models.  
These models provide a three dimensional visualization of 
combined drug behavior. Response surfaces are particularly 
useful in visualizing the predicted response for all drug 
combinations shown. Response surfaces for EI, loss of 
consciousness (LOR) and respiratory compromise (RC) 
(combination of respiratory depression and airway 
obstruction) can be combined to identify ideal concentration 
pairs and dosing regimens that meet clinician needs yet 
provide patient safety. 
Preliminary research must be conducted to collect the 
data required to build these response surfaces. Advances in 
technology allow further investigation to be done with 
modeling. Studies have developed pharmacokinetic and 
pharmacodynamic models for propofol1 and remifentanil.2 
With these models, it is possible to perform simulation 
studies of predicted patient response to a given stimulus over 
a wide range of drug ratios and dosing strategies. The cost 
functional will aid in the identification of those combinations 
that closest match the defined criteria. 
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Figure 1. Response surfaces for EI (A), LOR (B) and RC (C). The 
remifentanil-propofol drug combinations resulting in 5% (dotted line), 
50% (solid line) and 95% (dashed line) probabilities are shown.  
(A) EI was considered tolerated if it was placed mid-esophageal 
(~40 cm) without subject discomfort, as indicated by the subject raising 
their hand, gag reflex, coughing, or greater than 20% increase in 
baseline heart rate or blood pressure.  
(B) LOR was defined as OAA/S < 2, which coincides with a loss of 
response to shake and shout.  
(C) RC is generated from the combined data of airway obstruction and 
respiratory depression. 
III. METHODS 
 
Data used to construct the response surfaces were 
collected following the procedure outlined in the methods 
section of last year’s paper.3 For this study, surfaces for EI, 
LOR and RC were constructed (Fig. 1). Response surfaces 
were generated using the Greco construct (Eq. 1).4 The line 
on the surface formed when a plane drawn perpendicular to 
the effect axis intersects with the surface highlights all 
possible drug combinations that are expected to produce the 
same effect for a specific stimulus. This line is called an 
isobol, or iso-effect line, and is identified by the stimulus and 
probability associated with the effect (i.e. LOR C50 is the 
LOR 50% isobol, or drug combinations that produce a 50% 
probability of LOR). Isobols represent the “targets” define 
the different criteria.  
The criteria were defined in terms of isobols. The LOR C99 
isobol was defined as LOR. We wanted to minimize the 
amount of time effect site (brain) concentrations were above 
this line. The RC C95 isobol defined RC. We again wanted to 
minimize the amount of time above this line.  EI C95 isobol 
defined the target that must be reached for placement of the 
instrument in the esophagus. We wanted to reach this isobol 
quickly while minimizing the amount of time above it.  
During the study, drugs were administered using 
Stanpump (http://anesthesia.stanford.edu/pkpd). Simulations 
can be performed in Stanpump, but it is a time consuming 
process. Therefore, a MatLab (MathWorks, Natick, MA) 
implementation of Stanpump was built, thereby allowing us 
to run thousands of simulations and immediately process the 
results. 
To minimize the iteration matrix and avoid impractical 
solutions, we defined drug ranges and step sizes to match 
what is clinically relevant and feasible. The simulations 
assumed propofol and remifentanil would be combined and 
administered together. It was also assumed that propofol 
would always be 10 mg/mL. We investigated remifentanil 
concentrations from 0 to 25 µg/mL, incrementing by 1.25 
µg/mL each time. Because the drugs are combined, we 
assumed the infusion rate would be set by propofol. Rates 
from 10 to 150 µg/kg/min were investigated, with a step size 
of 10 µg/kg/min. We also investigated pretreatment with 
bolus injections ranging from 0 to 20 mL, incrementing by 1 
mL. The patient was assumed to be 55 years old, 75 kg and 
175 cm. All simulations were for a 60 minute procedure and 
were run for both a male and female subject. 
It was decided that the best approach would be to develop 
three independent cost functionals, each of which would 
evaluate just one criteria. These three independent 
functionals would then be weighted and combined to yield 
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the final score. By convention, the closer a score is to zero, 
the closer it is to meeting all the criteria. The cost functional 
inputs are: 
1. Time above RC C95 
2. Time above LOR C99 
3. Time to EI C95 
 
IV. RESULTS 
 
Previous work has shown that it is not possible to both 
instrument a patient’s airway and remain in the moderate 
sedation range.5 It is necessary to venture into deeper 
sedation for patients to tolerate instrumentation. Along with 
this deeper sedation come adverse effects such as LOR and 
RC. During data collection we observed that the most 
stimulating part of the procedure is the actual placing of the 
instrument. A patient can tolerate a placed instrument at 
lower drug levels. Therefore, more drug must be given up 
front, but it can then be reduced for the duration of the 
procedure. Because it is impossible to perform the procedure 
and avoid these adverse effects, we must instead devise a 
dosing regimen that minimizes the time a patient is at drug 
levels with high probabilities of them occurring. 
Of the 13,230 simulations, 2,887 (12%) never reach the EI 
C95 isobol. The average time above this isobol for the 
remaining runs is 29.8 minutes ± 26.6. As shown in Fig 2, 
the EI C95 isobol requires higher drug levels compared to 
LOR and RC. There is potential for serious complications if 
a patient remains at these drug levels for almost half of the 
procedure. It only takes a minute or two to instrument the 
airway. If we therefore only include those runs that are above 
EI C95 for at least 1 minute but not more than 2.5 minutes, 
we are left with 412 (3%). Their average time above the 
isobol is 1.75 minutes ± 0.4. 
The average time above LOR C99 of those same 412 runs 
is 6.7 minutes ± 11. We will need to be above this isobol for 
at least the amount of time allowed for EI. If we further 
consider just those runs that are above LOR C99 for less than 
6 minutes, we are left with 327 (2.5%). The average time 
above the isobol drops to 3.4 minutes ± 1.2. 
Finally, the mean time above the RC C95 isobol for these 
327 runs is 7.1 minutes ± 11.7. After limiting these to those 
runs that are above RC C95 for less than 7 minutes, 305 runs 
remain (2.3%). The average time above the isobol is 4.2 
minutes ± 0.6. This approach has therefore eliminated 97.7% 
of the simulations. These are shown in Table 1. 
 
Table 1. Table showing manual filtering criteria for the simulations. 
The first three columns indicate the filter criteria, if any, for each time. 
The fourth column indicates the number of runs that met the criteria. 
The last column shows the percentage of runs that met all criteria. 
 EI C95 LOR 
C99 
RC C95 # of 
Runs 
Percent 
Man #1 >0   10,343 78 
Man #2 1≤tme<2.5   412 3 
Man #3 1≤tme<2.5 <6  327 2.5 
Man #4 1≤tme<2.5 <6 <7 305 2.3 
 
 
Figure 2. The target isobols are shown with the results of one 
simulation. A 55 year old male, 75 kg and 175 cm was pretreated with a 
6 mL bolus of 10 mg/mL propofol combined with 10 µg/mL 
remifentanil. This was immediately followed with a 60 minute infusion 
at 40 µg/kg/min. Markers are displayed at whole minutes. 
 
After having manually filtered the simulations, we next 
attempted to develop a cost functional that would yield a 
similar selection. The simplest cost functional just adds the 
three times to create a score. A similar number of final 
simulations can be obtained by eliminating all runs with 
scores greater than 3.5 or equal to 0. This leaves 293 
simulations. However, they are all unique to those obtained 
previously. When manually selecting runs, all those that did 
not reach EI C95 were eliminated. When the cost functional 
was changed to subtract 1 from EC C95 time and to not 
assign a score to any run that did not reach EI C95, 311 
simulations were selected when a cutoff score of 9.5 was 
used. This time, only 87 runs were unique (28%). A third 
version eliminated all projects that were not above EI C95 for 
at least one minute, similar to the criteria used when 
manually selecting runs. Selecting just those runs with a 
score less than 9.8 resulted in 301 simulations being selected, 
of which 62 were unique (21%). 
After looking at the isobol shapes in Fig. 2, it was noted 
that RC C95 and EI C95 appeared to be concentric. This 
 
Table 2. Table showing cost functional algorithm development for 
filtering the simulations. The first three columns indicate the inclusion 
criteria, if any, and well as any modification done for each time. The 
fourth column indicates the score selection criteria. The fifth column 
shows the number of runs that met the criteria. The last column is the 
percentage of the number of runs indicated that were not included in 
the manually selected approach. 
 EI C95 LOR 
C99 
RC 
C95 
Score # of 
Runs 
Percent 
Unique 
CF #1 >0   <3.5 293 100 
CF #2 >0, tme-1   <9.5 311 28 
CF #3 >1, tme-1   <9.8 301 21 
CF #4 >1, tme-1  X <5.1 314 27 
CF #5 >1, 
2•(tme-1) 
tme-
2 
X <4.5 304 20 
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means the times should be highly correlated. Therefore, it is 
not necessary to include a time for both. After eliminating 
time above RC C95, 314 simulations were selected by using a 
cutoff score of 5.1, with 86 being unique (27%). It was noted 
that previously we had also used a cutoff time for EI C95 of 2 
minutes. When adding times, time above LOR C99 is almost 
always greater than EI C95 time because its isobol is lower on 
the plot. To give equal weight to both times, I doubled the 
weight of EI C95 (multiplied by 2) and subtracted 2 from the 
LOR C99 time. When using a cutoff score of 4.5, 304 runs 
were selected, 60 of which were unique (20%). These are all 
summarized in Table 2. 
 
V. DISCUSSION 
 
Both manual and automated dosing evaluations were able 
to yield similar simulation selections. The elimination of 
97.7% of simulations based upon evaluation criteria makes 
the task of selecting a drug ratio and dosing regimen more 
manageable. However, the filtering is a product of the 
method used. The approach taken in this study used time 
above three isobols. The selection might therefore identify 
the fastest procedure or the longest, etc. There are other 
parameters worthy of consideration when selecting a drug 
ratio and dosing regimen. For example, how long it takes for 
a patient to be reach the EI C95 isobol is important, as is how 
long it takes them to wake up once the infusions are turned 
off. Additionally, we tossed all runs that didn’t reach the EI 
C95 isobol. A better approach may be to use a combination of 
maximum probability obtained, the time to reach it and time 
above it as well as time to return of consciousness. 
It may also be worth including information about the 
drugs. Respiratory depression, the more dangerous 
component of respiratory compromise, is associated more 
with high remifentanil effect site concentrations. Onset of 
Airway obstruction, the more manageable component, 
occurs at high propofol effect site concentrations. Therefore, 
it is expected that a preferred dose would have a low 
remifentanil/high propofol drug ratio. While this information 
is incorporated already in the cost functional through 
respiratory compromise, it may be helpful to include it more 
directly. 
Because we are running simulations, we also have the 
benefit of knowing the equation that describes the lines. It 
may be possible to take advantage of the Greco equation (Eq. 
1), in whole or in part, to create a more dosing-dependent 
score. The isobol curves are calculated using this equation. It 
may also be possible to relate them somehow to develop an 
equation where the meaning of the score does not change if 
the isobol probability is changed.  
Isobols can be drawn for any probability. In hindsight I 
would propose lowering the RC isobol to C50. We do not 
want RC to occur so using a lower probability would 
increase the amount of time above it, increasing the score for 
being above it. Also, EI and RC isobols do not match at 
different probabilities. The cost functional should therefore 
include it. LOR, however, may be unnecessary. Unless the 
procedure requires the patient be alert, it may only be 
necessary to track RC. LOR does not provide any additional 
information about adverse effects. However, it does help 
predict wake up times after the infusion is turned off. 
Future versions of the cost functional should also consider 
if spontaneous breathing stops and for how long. 
Additionally, criteria for selecting the drug levels the balance 
of the procedure will take place at need to be developed. 
Finally, the focus of this study was to create a cost functional 
that selected the same runs identified through a manual 
process. Future work, including clinical trials, is necessary to 
select and validate a final drug dose and dosing regimen.  
 
VI. CONCLUSION 
 
A cost functional can be developed that will reasonably 
match manual filtering of simulation results. Eighty percent 
of the runs identified were identical to both methods. The 
cost functional could be used to eliminate 98% of the 
simulations, greatly reducing the task of evaluating the 
simulation results.  
Manually filtering the simulation results provides a 
baseline to compare the cost functional to. However, the 
techniques used are easily implemented in a program, 
thereby eliminating some post processing requirements. 
Also, we relied just on times for the manual filtering. A cost 
functional provides an opportunity to use more complex 
methods. Additional information should be included in the 
equation to selection of an optimal drug ratio and dosing 
scheme does not rely solely on times. Finally, the current 
score is not meaningful. Future work would modify the 
equation so the output would provide information about that 
run. So while this study looked at mimicking the results 
obtained by manually filtering, future work would improve 
upon it.  
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